December 7, 2012
Each week, we like to take a moment to boil down the biggest news from the most influential companies in the pharmaceuticals industry, and tell our viewers what that news means for you. We call that segment our Big Pharma Roundup.
In this week's installment, Johnson & Johnson (NYSE: JNJ ) has officially announced that former CEO William Weldon will be stepping down from the chairman position, with its current CEO as of April, Alex Gorsky, taking his place. In this video, Motley Fool health care analyst Brenton Flynn discusses some of the criticisms Weldon had been facing amid several large-scale recalls, as well as one event to pay attention to early next week.
In the world of health care, companies simply don't come any bigger than Johnson & Johnson. Many own the stock, but few understand its story. Offering everything from baby powder to biologics, critics think the company has spread itself too thin, becoming nothing more than a bloated corporate whale. Is this true, or is J&J a well-diversified giant that's perfect for your portfolio? Make sure you understand the full story behind the stock, along with its key opportunities and risks, by checking out our brand new premium report on Johnson & Johnson. To claim your copy simply click here now for instant access.